相关实验视频
Updated: Jun 4, 2025

Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
慢性病的-葡萄糖共运输体2抑制剂:为什么,什么时候,什么时候不
Muhammad M Javaid1, Rachel Frederick2, Sheema Itrat3
1FRCP, FASN, FRACP, Adjunct Clinical Associate Professor, Rural Health Mildura, Monash University, Melbourne, Vic; Affiliate Associate Professor, School of Medicine, Deakin University, Warrnambool, Vic; Staff Specialist Nephrologist and Physician, South West Healthcare, Warrnambool, Vic.
-葡萄糖共运输体2 (SGLT2) 抑制剂是一种安全有效的治疗方法,可减缓慢性病 (CKD) 的进展. 这些药物无论糖尿病状况如何都有利于患者,并建议大多数CKD患者在初级保健中服用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 是一个重大的全球健康挑战,其晚期与更高的死亡率,发病率和医疗保健成本有关.
- 早期干预以减缓CKD进展对于患者的治疗结果和经济节约至关重要.
研究的目的:
- 为全科医生提供基于证据的指导,说明如何在CKD患者中启动-葡萄糖共运输体2 (SGLT2) 抑制剂.
- 在初级保健机构为CKD管理提供临床决策的支持.
主要方法:
- 随机对照试验 (RCT) 的审查,评估SGLT2抑制剂在CKD患者.
- 分析关于减缓疾病进展的有效性证据在不同CKD阶段以及与糖尿病状况相关的证据.
主要成果:
- 有机试验表明,SGLT2抑制剂显著减缓CKD的进展.
- 在治疗慢性瘤方面,SGLT2抑制剂的益处在早期和晚期疾病阶段都很明显.
- 无论患者的糖尿病状况如何,SGLT2抑制剂的有效性都是一致的.
结论:
- SGLT2抑制剂代表了对CKD管理的有价值和安全的治疗选择,补充了现有的氨酸- ангиотензин-阿尔多斯特系统阻断剂.
- 在初级保健中,建议对大多数CKD患者考虑使用SGLT2抑制剂.
- 这些药物为改善慢性病的长期结果提供了一个有希望的策略.
更多相关视频
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
相关概念视频
Secondary Active Transport
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Dipeptidyl Peptidase 4 Inhibitors